Immuneering Corporation
IMRX
$3.95
-$0.09-2.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.90% | 21.58% | 12.25% | 0.98% | -2.68% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.97% | -25.89% | 0.70% | -1.04% | 1.04% |
| Operating Income | 0.97% | 25.89% | -0.70% | 1.04% | -1.04% |
| Income Before Tax | 10.54% | 35.85% | -2.52% | -2.51% | -5.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.54% | 35.85% | -2.52% | -2.51% | -5.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.54% | 35.85% | -2.52% | -2.51% | -5.16% |
| EBIT | 0.97% | 25.89% | -0.70% | 1.04% | -1.04% |
| EBITDA | 0.95% | 25.97% | -0.77% | 1.01% | -1.08% |
| EPS Basic | 50.84% | 69.16% | 22.89% | 15.52% | 13.07% |
| Normalized Basic EPS | 49.38% | 68.83% | 22.87% | 15.53% | 14.03% |
| EPS Diluted | 50.84% | 69.16% | 22.89% | 15.52% | 13.07% |
| Normalized Diluted EPS | 49.38% | 68.83% | 22.87% | 15.53% | 14.03% |
| Average Basic Shares Outstanding | 81.99% | 108.02% | 32.93% | 21.36% | 20.97% |
| Average Diluted Shares Outstanding | 81.99% | 108.02% | 32.93% | 21.36% | 20.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |